RB1 and cancer: Moreover, in pRb-mutated cancer cells, where entry into S phase is unimpeded, PARPi or PARP1 knockdown sensitized cells to DNA-damaging chemotherapeutics; thus, caution should be used when treating pRb mutated cancers with PARPi therapy [45].